PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection

PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection

Largest Series A financing round in Asia's diagnostic technology sector since 2019 underscores strong investor confidence in PHASE Scientific's breakthrough diagnostic technology and growth vision.Investment to accelerate R&D and commercialization of cutting-edge early disease detection technology for multiple cancers, women's…

Phase Scientific secures $34M and more digital health funding

Phase Scientific, a company developing urine-based diagnostics tests for early disease detection, announced it completed a $34 million Series A funding round.  A private equity fund managed by Asia-based Value Partners Group led the round, with backing from other new investors and existing global investors.  The biotechnology company's test Phasify uses urine concentration technology for molecular diagnostics, allowing for multi-cancer detection…

PHASE Scientific secures $34m for urine-based diagnostic technology

PHASE Scientific International has completed a Series A funding round, raising $34m for progressing the PHASIFY diagnostic.The post PHASE Scientific secures $34m for urine-based diagnostic technology appeared first on Medical Device Network.

Hong Kong's PHASE Scientific raises $34M Series A round to advance urine-based diagnostic technology for early disease detection

PHASE Scientific International Limited, a Hong Kong-based biotechnology company, announced Tuesday the successful completion of a $34 million Series A funding round. The firm said in a statement that this represents the largest Series A raise in Asia’s diagnostic technology sector since 2019, reflecting robust investor conviction in PHASE Scientific’s innovative PHASIFY technology and ambitious growth strategy. The funding round is led by a priv…

This is the largest Series A financing in the diagnostic technology field in Asia since 2019, fully reflecting investors’ high recognition of PhaseDa Biotech’s innovative technology and growth potential. The funds raised will be used to accelerate research and development breakthroughs in advanced technologies for early disease screening and further improve the commercialization of diagnostic solutions for various cancers, women's health and inf…